FAAH inhibitor: The anxiolytic efficacy of CBD may be a result of its ability to act as an enzymatic inhibitor of FAAH (fatty acid amide hydroxylase). FAAH is an enzyme responsible for metabolizing endocannabinoids such as anandamide, but when inhibited, these endocannabinoid concentrations are increased. Increased concentrations of endocannabinoids such as anandamide and 2-AG, both of which bind to peripheral CB1/CB2 receptor sites.
In regards to the use of CBD, one must be careful to choose a product that has little to no quantity of THC, especially if one lives in a state where it is illegal. Still, many high-quality products meet this criterion and are thus legal for usage. Please also note, there are not many studies on the use of each of these individual products, and therefore, users should start at lower doses and increase slowly. The idea is to arrive at the lowest dose that appears to exert a therapeutic benefit.
To compare the efficacy of the aforestated agents in reducing anxiety associated with the simulated public speaking task, researchers collected measures using the VAMS (Visual Analogue Mood Scale) and State-Trait Anxiety Inventory (STAI). Comparatively, ipsapirone (5mg) reduced anxiety induced by the simulated public speaking task, whereas CBD (400 mg) only decreased anxiety after the task. Valium (10 mg) reduced anxiety before and after the simulated public speaking task, but didn’t decrease anxiety during the speaking.
Cannabidiol did not reduce responses to negative emotional stimuli or reduce anxiety in healthy participants, according to a study published in Cannabis and Cannabinoid Research in 2017. Researchers tested participants' responses to negative images or words and threatening emotional faces and sensitivity to social rejection after taking oral cannabidiol.